TY - JOUR
T1 - Prognostic implications of receptor discordance between primary and recurrent breast cancer
AU - Matsumoto, Akiko
AU - Jinno, Hiromitsu
AU - Murata, Takeshi
AU - Seki, Tomoko
AU - Takahashi, Maiko
AU - Hayashida, Tetsu
AU - Kameyama, Kaori
AU - Kitagawa, Yuko
N1 - Funding Information:
This study was supported by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Publisher Copyright:
© 2014, Japan Society of Clinical Oncology.
PY - 2015/8/8
Y1 - 2015/8/8
N2 - Background: Discordance rates of hormone receptor (HR) and human epidermal growth factor-2 (HER2) status between primary and recurrent breast cancer were reported to be in the wide range of 10–40 %, although its prognostic relevance remains to be elucidated. Methods: Fifty-five breast cancer patients had biopsies or resections of recurrent lesions. Pathological assessments of the HR and HER2 status of primary and recurrent lesions were performed in a single laboratory at Keio University Hospital. Tumors were classified as luminal (HR+ and HER2−), luminal/HER2 (HR+ and HER2+), HER2 (HR− and HER2+), or triple negative (HR− and HER2−). Results: Discordance rates in estrogen receptor (ER), progesterone receptor (PgR) and HER2 status between primary tumors and recurrent lesions were 16.4, 30.9 and 10.2 %, respectively. Overall, 14 patients (25.5 %) changed subtypes at recurrent lesions. Patients with a gain in ER and PgR status had a significantly longer disease-free interval compared with the corresponding concordant-negative patients (ER: 99.0 vs. 18.5 months, p = 0.037, PgR: 141.0 vs. 24.4 months, p = 0.011). Patients with a loss of HER2 status experienced a trend toward shorter time to progression, compared with patients who maintained HER2 positivity (4.0 vs. 18.4 months, p = 0.051). Conclusions: Discordance in receptor status between primary and recurrent breast cancers were seen in 10–30 %. A gain in HR status was significantly associated with better prognosis.
AB - Background: Discordance rates of hormone receptor (HR) and human epidermal growth factor-2 (HER2) status between primary and recurrent breast cancer were reported to be in the wide range of 10–40 %, although its prognostic relevance remains to be elucidated. Methods: Fifty-five breast cancer patients had biopsies or resections of recurrent lesions. Pathological assessments of the HR and HER2 status of primary and recurrent lesions were performed in a single laboratory at Keio University Hospital. Tumors were classified as luminal (HR+ and HER2−), luminal/HER2 (HR+ and HER2+), HER2 (HR− and HER2+), or triple negative (HR− and HER2−). Results: Discordance rates in estrogen receptor (ER), progesterone receptor (PgR) and HER2 status between primary tumors and recurrent lesions were 16.4, 30.9 and 10.2 %, respectively. Overall, 14 patients (25.5 %) changed subtypes at recurrent lesions. Patients with a gain in ER and PgR status had a significantly longer disease-free interval compared with the corresponding concordant-negative patients (ER: 99.0 vs. 18.5 months, p = 0.037, PgR: 141.0 vs. 24.4 months, p = 0.011). Patients with a loss of HER2 status experienced a trend toward shorter time to progression, compared with patients who maintained HER2 positivity (4.0 vs. 18.4 months, p = 0.051). Conclusions: Discordance in receptor status between primary and recurrent breast cancers were seen in 10–30 %. A gain in HR status was significantly associated with better prognosis.
KW - Biopsy
KW - Breast cancer
KW - Discordance
KW - Prognosis
KW - Receptor
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=84938743046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938743046&partnerID=8YFLogxK
U2 - 10.1007/s10147-014-0759-2
DO - 10.1007/s10147-014-0759-2
M3 - Article
C2 - 25348193
AN - SCOPUS:84938743046
SN - 1341-9625
VL - 20
SP - 701
EP - 708
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 4
ER -
